Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

PUBLICATIONS SHOULD BE DELIVERED SEPARATELY USING A SPREADSHEET PROGRAM (EXCEL OR SHEETS)

Filter

Dec 2020 | From Akero Therapeutics

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

Jul 2018 | FROM EXTERNAL EXPERTS

A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling

Jul 2018 | From External Experts

FGF21 gene therapy as treatment for obesity and insulin resistance

Jun 2018 | FROM EXTERNAL EXPERTS

Recent advances in understanding and managing non-alcoholic fatty liver disease

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.